Showing results (21-30 of 71) with videos related to

Sort By:
Pageof 8
Journal of the National Cancer Institute|September 18, 2015
Prognostic Value of 25-hydroxyvitamin D3 Levels at Diagnosis and During Follow-up in Melanoma PatientsPhilippe Saiag, Philippe Aegerter, Dominique Vitoux, et al.
Cancer Research|December 7, 2019
Netrin-1 and Its Receptor DCC Are Causally Implicated in Melanoma ProgressionAmina Boussouar, Antonin Tortereau, Ambroise Manceau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2009
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteriaJedd D Wolchok, Axel Hoos, Steven O'Day, et al.
European Journal of Cancer (Oxford, England : 1990)|February 6, 2007
Clinical value of combined determination of plasma L-DOPA/tyrosine ratio, S100B, MIA and LDH in melanomaJean-Pierre Garnier, Sabine Letellier, Bruno Cassinat, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|February 5, 2005
ESHAP for primary cutaneous T-cell lymphomas: efficacy and tolerance in 11 patientsAmel Mebazaa, Alain Dupuy, Michel Rybojad, et al.
Melanoma Research|November 19, 2013
Vemurafenib in the French temporary authorization for use metastatic melanoma cohort: a single-centre trialFeriel Fennira, Cecile Pagès, Pierre Schneider, et al.
The Journal of Clinical Investigation|August 28, 2013
Human skin carcinoma arising from kidney transplant-derived tumor cellsLaurence Verneuil, Mariana Varna, Philippe Ratajczak, et al.
Expert Review of Anticancer Therapy|December 22, 2018
Management of immune-related adverse events resulting from immune checkpoint blockadeBarouyr Baroudjian, Dimitri Arangalage, Stefania Cuzzubbo, et al.
Cancer Immunity|October 21, 2010
Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trialsJedd D Wolchok, Jeffrey S Weber, Omid Hamid, et al.
European Journal of Cancer (Oxford, England : 1990)|September 18, 2012
Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trialMadeleine Duvic, Reinhard Dummer, Jürgen C Becker, et al.
Pageof 8